Distinct predictive factors influence on achievement of early molecular response by frontline imatinib in chronic phase chronic myeloid leukemia

Highlights • Some biological factors were associated with achievement of early molecular response. • Some factors for early molecular response achievement can be modifiable. • Continuing the optimal dose intensity until 6 months is important for better outcomes.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia research 2015-04, Vol.39 (4), p.411-418
Hauptverfasser:	Lee, Sung-Eun, Choi, Soo Young, Oh, Yun Jeong, Kim, Soo-Hyun, Song, Hye-Young, Yoo, Hea-Lyun, Lee, Mi-Young, Chae, Moon-Jung, Kang, Ki-Hoon, Hwang, Hee-Jeong, Jang, Eun-Jung, Kim, Dong-Wook
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Antineoplastic Agents - therapeutic use Benzamides - therapeutic use Biomarkers, Tumor - genetics Chronic myeloid leukemia Early molecular response Female Follow-Up Studies Fusion Proteins, bcr-abl - genetics Hematology, Oncology and Palliative Medicine Humans Imatinib Imatinib Mesylate Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology Male Middle Aged Neoplasm Staging Piperazines - therapeutic use Prognosis Pyrimidines - therapeutic use Real-Time Polymerase Chain Reaction Reverse Transcriptase Polymerase Chain Reaction RNA, Messenger - genetics Survival Rate Time Factors Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Some biological factors were associated with achievement of early molecular response. • Some factors for early molecular response achievement can be modifiable. • Continuing the optimal dose intensity until 6 months is important for better outcomes.
ISSN:	0145-2126 1873-5835
DOI:	10.1016/j.leukres.2015.01.011